chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Site: Bruising at Injection Site-Mild, Systemic: Chills-Medium, Systemic: Dizziness / Lightheadness-Severe, Systemic: Flushed / Sweating-Medium, Systemic: Hypotension-Medium, Systemic: Nausea-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Systemic: Weakness-Mild, Additional Details: cold extremities, low bp, anxiety reported by pt, nausea numbness and tingling in fingers, got shot at 10:14am, pt complained of feelinng dizzy, pt layed down with feet elevated at 10:20am and atempted to get BP but pt was moving around and wasnt able to get readings, called EMS, fire dept arrived at 10:30am and ran bp of 108/60, with hr=55 at 10:33am and took patient outside on gerny for further tests, no brusing at injection site, wont let me complete without choosignan option
vesicular rash to face, head, chest, belly, arms & legs w/fever & deep cough-sore throat, & rash spreading to all body;given med;
Redness, swelling, tender to touch around the area of DTaP/IPV and MMR injections imm. after. These symptoms increased over next 4 days, and slowly reduced with BENADRYL. Full recovery by 7/10/12.
Cough; Pain in ears; Pain in throat; ear infection; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough), EAR PAIN (Pain in ears), OROPHARYNGEAL PAIN (Pain in throat) and EAR INFECTION (ear infection) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jul-2021, the patient experienced COUGH (Cough), EAR PAIN (Pain in ears), OROPHARYNGEAL PAIN (Pain in throat) and EAR INFECTION (ear infection). At the time of the report, COUGH (Cough), EAR PAIN (Pain in ears), OROPHARYNGEAL PAIN (Pain in throat) and EAR INFECTION (ear infection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   The patient was given antibiotic.   This case was linked to MOD-2021-284101 (Patient Link).; Sender's Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested
All were Normal Known Side Effects... Started at 2/5, approx 8pm: Very Sore Injection Site Started at 2/6, approx 6pm: Mild Fever (100), Fatigue, Headache, All-over Muscle and Joint Body Aches, All-over Chills
No adverse event from the vaccine, Incorrect vaccine given. Patient was given PREVNAR 13 should have received pneumococcal conjugate vaccine 23.
inflammatory reaction; fever; chills; myalgia; arthralgia; This spontaneous case was reported by a patient and describes the occurrence of INFLAMMATION (inflammatory reaction), PYREXIA (fever), CHILLS (chills), MYALGIA (myalgia) and ARTHRALGIA (arthralgia) in a male patient of an unknown age who received mRNA-1273 (Spikevax) (batch no. 016B22A) for COVID-19 prophylaxis.     Patient did not report any medical history or condition. He said he has nothing that would be related to his reactions.     On 15-Jul-2022, the patient received fourth dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLAMMATION (inflammatory reaction), PYREXIA (fever), CHILLS (chills), MYALGIA (myalgia) and ARTHRALGIA (arthralgia). At the time of the report, INFLAMMATION (inflammatory reaction), PYREXIA (fever), CHILLS (chills), MYALGIA (myalgia) and ARTHRALGIA (arthralgia) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication was reported.  Patient took 1st dose 07-Mar-2021 with the lot number 003A21A, 2nd dose 05-Apr-2021 with the lot number 032B21A and 3rd dose 27-Nov-2021 with the lot number 036C21A.  He stated he never had any reaction to any other vaccine except inflammatory reaction, fever, chills, myalgia, and arthralgia.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-745277, MOD-2023-745287 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-745277:Monovalent Dose MOD-2023-745287:Bivalent dose
Headache and neck pain sporadic and occurs predominantly in late afternoon/evening.  This is continuing on 2/16/2021.
No adverse event; received a dose of Moderna COVID-19 Vaccine Biavlent before he got his 2 doses of the primary series; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (received a dose of Moderna COVID-19 Vaccine Biavlent before he got his 2 doses of the primary series) and NO ADVERSE EVENT (No adverse event) in an 18-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 021H22A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 23-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .5 milliliter. On 23-Nov-2022, the patient experienced INCORRECT DOSE ADMINISTERED (received a dose of Moderna COVID-19 Vaccine Biavlent before he got his 2 doses of the primary series). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (received a dose of Moderna COVID-19 Vaccine Biavlent before he got his 2 doses of the primary series) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (received a dose of Moderna COVID-19 Vaccine Biavlent before he got his 2 doses of the primary series).    Concomitant medications details were not reported by the reporter.  Reportedly, Patient did not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Treatment details were not reported by the reporter.
Woke up with vertigo on Sunday, 7/24. Not able to get out of bed except to use bathroom. Stayed in bed most of day. On Monday,  was able to sit up for a period of time in the afternoon.  Have improved each day but still slight motion sickness if watching too much movement on TV or if I move my head too much.  On Thursday,  7/28, popped a blood vessel in my right eye which is healing now. No pain or discomfort in eye. Have had both vertigo and blood vessel issue in the past (pre-covid) but it has been several years since, and never within days of each other. Did not go to doctor
The evening after receiving the first vaccine I began having tinges of pain in left side of abdomen.  Worsened each day until the the 4th day a rash of welts broke out from my navel to middle of my back on my left side.
Patient stated she was experiencing SOB, lightheaded, and numbness or tingling. She was given water and crackers. EMS was called vitals HR 84  BP 210/72  98% O2. Patient stated she feeling better and released and she was asked to follow up with MD regarding BP.
Didn?t know these could vax related at the time: Chronic tinnitus to this day, double vision (somewhat better but still bad days), leg cramping, but unusual--starts at lower calf and I feel it crawling up. Foot at 45° angle and won't flex until I stand on toes then force my knee down.  Then it goes away.
joint pain; fatigue; low grade fever; myalgia; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 06Oct2021 12:00 (Lot number: EW0217) at the age of 37 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EL3247, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM, Route of Administration: Intramuscular), administration date: 10Feb2021, when the patient was 37 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EL3247, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM, Route of Administration: Intramuscular), administration date: 20Jan2021, when the patient was 37 years old, for Covid-19 immunization. The following information was reported: ARTHRALGIA (non-serious) with onset 07Oct2021 08:00, outcome "recovering", described as "joint pain"; FATIGUE (non-serious) with onset 07Oct2021 08:00, outcome "recovering", described as "fatigue"; PYREXIA (non-serious) with onset 07Oct2021 08:00, outcome "recovering", described as "low grade fever"; MYALGIA (non-serious) with onset 07Oct2021 08:00, outcome "recovering", described as "myalgia". Therapeutic measures were taken as a result of arthralgia, fatigue, pyrexia, myalgia.  Additional information: Treatment received for adverse event was Ibuprofen. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not been tested for COVID-19. There was no known allergies. Other medical history was none.   No follow-up attempts are possible. No further information is expected.
PATIENT CAME IN THIS MORNING (1/14/19) STATING THAT SHE HAD A PAIN THAT SHOT DOWN HER ARM AND UP INTO THE SIDE OF HER HEAD AND HAD  NAUSEA AS WELL. SHE SAID IT LASTED FOR ABOUT 24 HOURS THEN WENT AWAY. SHE WAS UNABLE TO REALLY LEAVE THE HOUSE OR DO ANYTHING THE DAY AFTER THE SHOT DUE TO HOW IT MADE HER FEEL. SHE STATES SHE FEELS FINE NOW AND WILL STILL GET THE 2ND DOSE WHEN IT IS DUE.
Patient needs the 3rd dose; 1st dose April 2022, 2nd on 24Aug2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a elderly female patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis, HAB (Twinrix) for prophylaxis and hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (1st dose received on April 2022).   On 24th August 2022, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, the patient did not receive the 3rd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On 24th August 2022, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device and not applicable after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the drug dose administration interval too long and incomplete course of vaccination were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 31-OCT-2022 Reporter's Comment: The reporter was a pharmacist. The reporter reported that the patient received Twinrix vaccine late than recommended time frame. The reporter stated that the patient did not reported the symptoms. The reporter did not had the patient full date of birth, exact date of the first dose, lot and expiration date of the 2nd dose. The reporter reported that the patient need the 3rd dose but reporter did not know if the patient should restart the series. The reporter consented to follow up. Additional supportive information: The patient received 2nd dose of Twinrix late than recommended time frame, which led to lengthening of vaccination schedule. Till the time of reporting, the patient did not receive the 3rd dose of Twinrix vaccine, which led to incomplete course of vaccination. This case has been linked with case US2022118619 reported by same reporter.; Sender's Comments:  US-GSK-US2022118619:Same reporter
Moderna vaccine was administered after the vaccines 30 day refrigerator BUD of 8/5/22.   Moderna notified. Email response from Moderna received and stated: "The vaccine administered on or before August 22, 2022 from lot number 064A22A maintained the activity necessary to protect against the SARS-CoV-2 (COVID-19) virus at time of administration."
more than 42 days for administration of second dose; Trouble bending; pain in the lower back; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (Trouble bending), BACK PAIN (pain in the lower back) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 42 days for administration of second dose) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027H1B and 004D21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in 2021. Concomitant products included ATORVASTATIN for an unknown indication.   On 12-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Dec-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 42 days for administration of second dose). In December 2021, the patient experienced MOBILITY DECREASED (Trouble bending) and BACK PAIN (pain in the lower back). On 04-Dec-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 42 days for administration of second dose) had resolved. At the time of the report, MOBILITY DECREASED (Trouble bending) had not resolved and BACK PAIN (pain in the lower back) was resolving.            Patient reported anti-inflammatory medicine as treatment medication   This case was linked to MOD-2021-435447, MOD-2021-435447 (Patient Link).
Patient came in to office for flu vaccine 10/4/21 at 10:55 am. At 4:17 pm mother of the child called stating that the patient has red hives all over his body. The rash mainly appeared on both of his legs, arms abdomen and on his face. The provider advised the mother to start the child on children's Benadryl every 6 hours as needed.
Narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/03, Pfizer, dose #2 08/19 COVID sab, result: detected 08/20 pt cc: no symptoms exposure: unknown
/Win 24 hrs of getting pneumonia & flu shot-area around the site of injection developed a rash /w an enlarging of the lymph gland under the arm. Lasted for about a wk. No TX.
Information has been received from a health care worker concerning a patient who was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot 647724/0946N). Subsequently the patient developed a red, puffy rash, The patient went to the emergency room. The outcome was unknown. No product quality complaint was involved. The health care worker noted that he had sold the vaccines to the doctors office and they were returned to him because of the AE's. It was also reported that two other patients were vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot 647724/0946N) and developed an AE (WAES0410USA02477). Additional information has been requested.
For my 1st dose of Moderna I experienced muscle pain at the site of injection and was tired the next day. I had no reaction for the 2nd dose. For the 3rd dose, I experienced what seemed like a panic attack with all my muscles shaking for 15 minutes (that was 9 hours after the injection). After it went away, I had cold sweat all night, a low fever, and muscle pain. The whole next day I had a low fever, felt nauseous, had swollen gland (armpit, throat, and base of my spine), and could barely walk as I had intense pain all over my body. On the second day, I currently have no more fever, I am less tired and the muscle pain is not as intense. I am able to get out of bed but I do have swollen gland on the right side of my throat and have an ear/throat ache. Before getting the vaccine, I was sick for 3 weeks with a virus (got 4 covid test negative) that seemed like a sinus infection and was diagnosed with low level of iron.
tested positive for Covid; This is a spontaneous report from a contactable consumer, the patient, via a Pfizer-sponsored program. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 20Apr2021 as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. It was unknown if the patient was pregnant. On an unspecified date in Apr2021, the patient tested positive for COVID-19. Her second dose was scheduled for 11May2021 and the patient queried if she needed to reschedule her second dose. The clinical outcome of "tested positive for COVID" was unknown.  Information on lot number has been requested.
Middle of July: I had problems - pain in my right leg - excruciating. They did an ultrasound - had a very large blood clot in my leg. The person doing an ultrasound asked if I had a COVID vaccine recently. My doctor gave me Medications -at first they gave me a series of shots for it (self injections) (blood thinner). Pradaxa is current medication for it (blood thinner).  I just had follow up by email with my doctor - if I don't stay on it, I have up to 40% chance re-occurrence.
administer monovalet moderna covid 19 booster vaccine  on 09/02/22 to- patient  and on 09/06/2022  monovalent moderna covid 19 vaccine administered to two other patients  Toatal 3 people got Monovalet moderna covid 19 vaccine after 08/31/2022
Information has been received from a 64 year old female patient with none pertinent medical history and none drug reactions/allergies referring to herself. On 19-JAN-2015 the patient was vaccinated with a dose of ZOSTAVAX (route, lot#, dose and frequency unknown). There was none concomitant medication. On 21-JAN-2015, the patient experienced pain and soreness, redness and warm at the injection site and a headache. The patient also stated that the redness was bigger than a 50 cent piece. There was no treatment given for the adverse events. None lab diagnostics studies were performed. The patient sought medical attention via calling pharmacist. The outcome of the adverse events was reported as not recovered/not resolved. The relationship of the adverse events and ZOSTAVAX was not reported. Additional information has been requested.
Pt came in c/o severe itching with bumps on face and very reddened in color. Started c/o irritation to throat and was scratching all over.
some discomfort shoulder pain in the upper arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (some discomfort shoulder pain in the upper arm) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025620A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced VACCINATION SITE PAIN (some discomfort shoulder pain in the upper arm). On 19-Jan-2021, VACCINATION SITE PAIN (some discomfort shoulder pain in the upper arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
A report was received from a health care professional on 10/30/03, concerning an unspecified number of vaccinees under 4 years of age who inadvertently received Fluvirin on an unspecified date. No adverse effects had occurred at the time of report. There was insufficient information to determine the reporter's causality assessment. Update 1, 12/01/03: Follow up information received from a health care professional indicated that a 16 month old female vaccinee inadvertently received Fluvirin on 10/11/03 and had not experienced any adverse event at the time of the report. No follow up pending, all information received. Cross reference: PJP200300957, PJP200400013, PJP200400014, PJP200400015, PJP200400016, PJP200400017, PJP200400018, PJP20040019, PJP200400020, PJP200400021, PJP200400022, PJP200400023.
kidney pain; This spontaneous case was reported by a consumer and describes the occurrence of RENAL PAIN (kidney pain) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-May-2021, the patient experienced RENAL PAIN (kidney pain). At the time of the report, RENAL PAIN (kidney pain) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
(+) arching back; (+) screaming after waking up; (+) staring spells; lump in (L) thigh (injection site).
48 hrs after Tdap and MENACTRA vaccines developed erythem, urticarial 13.5 x 11.5 cm rash over (L) deltoid (site of injections). No fever.
New-onset dermatographism- raised red welts on skin with minor scratching, last for 5 to 10 minutes, not pruritic
This spontaneous report was received from the registered nurse refers to an unknown number of patients of unknown age and gender. On an unknown date, the patient was vaccinated with RECOMBIVAX HB (dose, route and lot were not reported). On an unknown date, the patients received improperly stored   RECOMBIVAX HB. No adverse symptoms reported. At the time of the report the action was not reported. All telephone attempts to obtain follow-up information have been unsuccessful.  Additional information was received from a registered nurse concerning a 1 day male patient. Patient's birth weight was 5 lb 5 oz with 0 siblings. Patient was vaccinated with RECOMBIVAX HB the same day that he was born (27-MAY-2014) at 10:47 AM. Lot number J012520; Exp. Date: 30-JAN-2016.  The vaccine storage temp dropped to 0-1 degrees on 18 different episodes between May 14th and July 21st (unspecified year) according to min/max. All recorded temps are within 2-8 degrees. Additional information is not expected since all follow ups requested to complete the case were received.
R cervical lymph swelling/tenderness with palpation (Jan 15 2009). Hives and itching on neck and extremities 12 Jan 2009. Seen and treated with PREDNISONE.
My symptom started on August 23rd.  I had loss of smell. I had fatigue and was tired.  I had sore throat.  I did not a fever.  I went and got a Covid-19 test, came back positive.  My symptom lasted for about 10 days.  The fatigue was ongoing.  It feels like someone is pulling on my chest.
Bodyaches, sweats, chills, fast heart rate(130?s) and dizziness, felt like I could faint.  Eyes felt like they moved funny and threw off my balance.  Had to hold onto wall. Symptoms started  about 9 hours after vaccine. Still having weird balance issues when walking and slight bodyaches and I am over 36 hours after vaccine.